In this subset of patients, anti-IL-Rα (benralizumab) showed a significant reduction in both circulating and sputum numbers of mature eosinophils and EoP cells, suggesting that targeting IL-5Rα+ cells decreases EoP cell numbers both systemically and within the airways, thereby attenuating the potential IL-5–driven in situ eosinophilopoietic processes that may contribute to persistent airway eosinophilia in patients with severe, prednisone-dependent asthma [155]. The gene discussed is IL5RA; the disease is asthma.